Cidara Therapeutics to Participate in the World Antiviral Congress 2022
11/23/2022 - 08:00 AM
SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.
The panel will discuss pandemic preparedness and therapeutic approaches, including predictions on the next viral threat, development of broad-spectrum drugs and platforms to engineer novel therapeutics.
Panel Details:
Title : Therapeutic approaches to pandemic preparednessLocation: Loews Coronado Bay Resort, San Diego, CA, Congress Room 4Session Date/Time : December 1, 2022, at 8:20 – 9:30 a.m. PST
To register and view the full congress schedule, visit the World Antiviral Congress’ website here .
About Cidara Therapeutics ® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
MEDIA CONTACT:
CDTX Rankings
#734 Ranked by Stock Gains
CDTX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
San Diego
About CDTX
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
